Bimatoprost Implant System + Timolol Maleate Ophthalmic Solution, 0.5%
Phase 3Recruiting 0 watching 0 views this weekπ Rising
72
Development Stage
β
Pre-clinicalβ
Phase 1β
Phase 24
Phase 35
ApprovedIndication / Disease
Cataract
Conditions
Cataract, Glaucoma, Ocular Hypertension
Trial Timeline
Oct 15, 2025 β Mar 31, 2031
NCT ID
NCT07218783About Bimatoprost Implant System + Timolol Maleate Ophthalmic Solution, 0.5%
Bimatoprost Implant System + Timolol Maleate Ophthalmic Solution, 0.5% is a phase 3 stage product being developed by SpyGlass Pharma for Cataract. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07218783. Target conditions include Cataract, Glaucoma, Ocular Hypertension.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07218796 | Phase 3 | Recruiting |
| NCT07218783 | Phase 3 | Recruiting |
Competing Products
20 competing products in Cataract